Skye Bioscience Q1 2025 10-Q Filed
Ticker: SKYE · Form: 10-Q · Filed: May 8, 2025 · CIK: 1516551
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
Skye Bioscience Q1 2025 10-Q is in: check financials for cash, debt, and equity.
AI Summary
Skye Bioscience, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported financial results for the first quarter of 2025, detailing its assets, liabilities, and equity. Specific financial figures for cash, accounts receivable, and other assets were provided, alongside liabilities such as accounts payable and accrued expenses. The filing also outlines the company's equity structure, including common stock and additional paid-in capital.
Why It Matters
This filing provides investors with a quarterly update on Skye Bioscience's financial health and operational performance, crucial for understanding its current standing and future prospects.
Risk Assessment
Risk Level: medium — As a biotech company, Skye Bioscience faces inherent risks related to drug development, regulatory approvals, and market competition, which are not fully detailed in this financial summary.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 2025-05-08 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
- 2025-01-01 — Quarter Start Date (Marks the beginning of the first quarter of 2025.)
Key Players & Entities
- Skye Bioscience, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250508 (date) — Filing date
- San Diego, CA (location) — Company's business and mailing address
- Emerald Bioscience, Inc. (company) — Former company name
- Nemus Bioscience, Inc. (company) — Former company name
FAQ
What was Skye Bioscience's cash position as of March 31, 2025?
The filing indicates financial data for the period ending March 31, 2025, but specific cash amounts are not detailed in the provided header information.
What is the company's primary business segment?
The company's primary business segment is Pharmaceutical Preparations, with SIC code 2834.
When did Skye Bioscience change its name from Emerald Bioscience, Inc.?
Skye Bioscience, Inc. changed its name from Emerald Bioscience, Inc. on March 25, 2019.
What is the company's state of incorporation?
Skye Bioscience, Inc. is incorporated in Nevada (NV).
What was the fiscal year end for Skye Bioscience?
The company's fiscal year ends on December 31st.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Skye Bioscience, Inc. (SKYE).